Scott Collins
About Scott Collins
Scott Collins serves as the Senior Vice President and Head of Market Access at BridgeBio, where he has worked since 2021. He oversees various functions including pricing, HEOR, payer relations, and patient services, drawing on extensive experience in market access and reimbursement across multiple pharmaceutical companies.
Work at BridgeBio
Scott Collins serves as the Senior Vice President and Head of Market Access at BridgeBio, a position he has held since 2021. In this role, he oversees various functions critical to market access, including Pricing, Health Economics and Outcomes Research (HEOR), Payer Relations, Distribution, Contracting, Reimbursement, HUB operations, and Patient Services. His strategic initiatives in market access have been a significant focus since his arrival at the company, contributing to the overall mission of BridgeBio in the pharmaceutical industry.
Background
Scott Collins has a diverse professional background in market access and reimbursement operations within the pharmaceutical sector. He began his career at Cyberonics as a Reimbursement Manager from 2006 to 2007. He then moved to Millennium Pharmaceuticals, where he worked as Associate Director of Reimbursement for the West region from 2007 to 2010. Following this, he held positions at Shire Pharmaceuticals and Pharmacyclics, where he further developed his expertise in market access strategies.
Education and Expertise
Scott Collins holds a Bachelor of Science degree in Business and Organizational Communication from San Francisco State University, where he studied from 1996 to 1999. Additionally, he studied Architecture at California College of the Arts. His educational background supports his extensive experience in market access and reimbursement operations across multiple pharmaceutical companies, equipping him with the skills necessary for his current role.
Achievements
Throughout his career, Scott Collins has been involved in various strategic market access initiatives. His roles at different pharmaceutical companies, including Shire Pharmaceuticals and Pharmacyclics, have allowed him to develop a comprehensive understanding of reimbursement operations and market access strategies. His leadership at BridgeBio reflects his commitment to enhancing market access for innovative therapies.